Literature DB >> 17326061

Coronary microvascular reactivity is only partially predicted by atherosclerosis risk factors or coronary artery disease in women evaluated for suspected ischemia: results from the NHLBI Women's Ischemia Syndrome Evaluation (WISE).

Timothy R Wessel1, Christopher B Arant, Susan P McGorray, Barry L Sharaf, Steven E Reis, Richard A Kerensky, Gregory O von Mering, Karen M Smith, Daniel F Pauly, Eileen M Handberg, Sunil Mankad, Marian B Olson, B Delia Johnson, C Noel Bairey Merz, George Sopko, Carl J Pepine.   

Abstract

BACKGROUND: Altered coronary reactivity is frequent in women with findings of myocardial ischemia without significant obstructive disease. This suggests a defect in coronary microvascular function. The adenosine-related component of this altered reactivity has been described in male and mixed gender populations, while the factors influencing this component of coronary reactivity in symptomatic women have received limited attention. Accordingly, the relationship between adenosine-related microvascular coronary reactivity and risk factors in symptomatic women evaluated for suspected ischemia remains uncertain. HYPOTHESIS: Abnormal coronary microvascular reactivity to adenosine is predicted by atherosclerosis risk factors in women.
METHODS: As part of the NHLBI-sponsored Women's Ischemia Syndrome Evaluation (WISE), we investigated the relationship between risk factors and coronary microvascular reactivity as flow velocity reserve to intracoronary adenosine (CFVR(Ado)) in 210 women referred for angiography to evaluate suspected ischemia.
RESULTS: Univariate analyses identified associations between CFVR(Ado) and multiple risk conditions; however, after adjusting for age, none remained significant. The best multivariable model using combinations of risk conditions to predict CFVR(Ado) yielded an R2 of only 0.18.
CONCLUSIONS: Among women with suspected ischemia, risk factors account for <20% of observed variability in CFVR(Ado). Therefore, other as yet unidentified factors must primarily account for coronary microvascular reactivity to adenosine. Copyright (c) 2007 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17326061      PMCID: PMC6653045          DOI: 10.1002/clc.19

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  41 in total

1.  Invasive coronary vasoreactivity testing to diagnose microvascular dysfunction in women.

Authors:  Alison L Bailey; Susan S Smyth
Journal:  JACC Cardiovasc Interv       Date:  2012-06       Impact factor: 11.195

Review 2.  Microvascular angina and the continuing dilemma of chest pain with normal coronary angiograms.

Authors:  Richard O Cannon
Journal:  J Am Coll Cardiol       Date:  2009-09-01       Impact factor: 24.094

Review 3.  Etiopathogenesis of microvascular angina: caveats in our knowledge.

Authors:  S R Mittal
Journal:  Indian Heart J       Date:  2014-11-04

Review 4.  Ischemia and No Obstructive Coronary Artery Disease (INOCA): Developing Evidence-Based Therapies and Research Agenda for the Next Decade.

Authors:  C Noel Bairey Merz; Carl J Pepine; Mary Norine Walsh; Jerome L Fleg
Journal:  Circulation       Date:  2017-03-14       Impact factor: 29.690

5.  Current Diagnostic and Therapeutic Strategies in Microvascular Angina.

Authors:  Bryn Mumma; Nathalie Flacke
Journal:  Curr Emerg Hosp Med Rep       Date:  2015-03

6.  Cardiac risk factors and myocardial perfusion reserve in women with microvascular coronary dysfunction.

Authors:  Megha Agarwal; Chrisandra Shufelt; Puja K Mehta; Edward Gill; Daniel S Berman; Debiao Li; Behzad Sharif; Ning Li; C Noel Bairey Merz; Louise E J Thomson
Journal:  Cardiovasc Diagn Ther       Date:  2013-09

Review 7.  Cardiac Syndrome X: update 2014.

Authors:  Shilpa Agrawal; Puja K Mehta; C Noel Bairey Merz
Journal:  Cardiol Clin       Date:  2014-06-02       Impact factor: 2.213

8.  Five-Year Follow-Up of Coronary Microvascular Dysfunction and Coronary Artery Disease in Systemic Lupus Erythematosus: Results From a Community-Based Lupus Cohort.

Authors:  Vaneet K Sandhu; Janet Wei; Louise E J Thomson; Daniel S Berman; Jay Schapira; Daniel Wallace; Michael H Weisman; C Noel Bairey Merz; Mariko L Ishimori
Journal:  Arthritis Care Res (Hoboken)       Date:  2020-06-04       Impact factor: 4.794

Review 9.  Gender and anti-thrombotic therapy: from biology to clinical implications.

Authors:  Rossella Marcucci; Gabriele Cioni; Betti Giusti; Cinzia Fatini; Lorenza Rossi; Maddalena Pazzi; Rosanna Abbate
Journal:  J Cardiovasc Transl Res       Date:  2014-01-28       Impact factor: 4.132

Review 10.  Coronary microvascular dysfunction: an update.

Authors:  Filippo Crea; Paolo G Camici; Cathleen Noel Bairey Merz
Journal:  Eur Heart J       Date:  2013-12-23       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.